Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787111 · ClinicalTrials.gov registry record · Phase 3
Extended Management and Measurement of Autism
A Phase 3 study, sponsored by Neuropharm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT00787111: Clinical Trial Phase 3 study, sponsored by Neuropharm.
NCT00787111 is a Phase 3 study that was terminated before completion, run by Neuropharm. The registered enrollment target is 128 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00787111, a Phase 3 study, was terminated before completion, sponsored by Neuropharm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month period.
Interventions
- DRUG Fluoxetine (prozac)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Why NCT00787111 stopped before completion
NCT00787111 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine (prozac) is the first listed.
NCT00787111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00787111 about?
NCT00787111 is a clinical study titled "Extended Management and Measurement of Autism". This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month perio...
What is the current status of trial NCT00787111?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2008-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00787111?
The interventions under investigation include: Fluoxetine (prozac) (DRUG).
Who is sponsoring clinical trial NCT00787111?
This trial is sponsored by Neuropharm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00787111's enrollment target sits among peer trials
128 1601st of 2000 higher than 399 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia